0RQJ.L - Saniona AB (publ)
| Chiusura precedente | 7,03 |
| Aperto | 7,48 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 7,48 - 7,54 |
| Intervallo di 52 settimane | 2,76 - 8,33 |
| Volume | |
| Media Volume | 3.066 |
| Capitalizzazione | 1,292M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -7,39 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSaniona AB’s Nomination Committee for the Annual General Meeting 2023
PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting 2023. Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On Septembe
- GlobeNewswire
Saniona publishes its interim report for the third quarter of 2022
Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss was SEK 17.5 M (-93.7 M)Operating profit/loss was SEK -203.1 M (-286.7 M)Net profit/loss was SEK -204.4 M (-281.8 M)Basic earnings/loss per share was SEK 0.28 (-1.50)Basic earnings/loss per share was SEK -3.28 (-4.52)Diluted earnings/loss per share were SEK 0.28 (-1.50)Diluted earnings/loss
- GlobeNewswire
Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies
PRESS RELEASE November 3, 2022 SAN903 has finalized preclinical development and fulfilled other requirements for clinical developmentPotential first-in-class compound offers a new treatment paradigm for inflammatory and fibrotic diseases Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that SAN903 is ready to start the regulatory process for entering Phase 1 clinical trials either by Saniona alone or together with a partner following successful completion of pre
- GlobeNewswire
Saniona extends runway and amends loan agreement with Formue Nord
PRESS RELEASE September 30, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that Saniona and Formue Nord Fokus A/S (Formue Nord) have agreed to the change the terms of the loan agreement of June 30, 2021. Saniona has repaid SEK 15 million of the loan and the maturity date for the outstanding loan value has been changed from June 30, 2023, to January 31, 2024. The current cash position is consequently expected to fund the planned activities until January 20
- GlobeNewswire
Saniona publishes its interim report for the second quarter of 2022
Three Months Ended June 30, 2022 (2021)Six Months Ended June 30, 2022 (2021)Revenue was SEK 3.0 M (1.9 M)Revenue was SEK 9.6 M (5.3 M)Operating profit/loss was SEK -91.8 M (-103.6 M)Net profit/loss was SEK -88.6 M (-103.9 M)Operating profit/loss was SEK -225.0 M (-197.7 M)Net profit/loss was SEK -221.9 M (-187.3 M)Basic earnings/loss per share was SEK -1.42 (-1.67)Basic earnings/loss per share was SEK -3.56 (-3.00)Diluted earnings/loss per share were SEK -1.42 (-1.67)Diluted earnings/loss per sh
- GlobeNewswire
Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022
PRESS RELEASE August 18, 2022 Today, on August 18, 2022, an extraordinary general meeting was held in Saniona AB. A summary of the adopted resolution follows below. The resolution was adopted with the required majority of votes. Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants The extraordinary general meeting resolved in accordance with the proposal from the board of directors to adopt an employee option program for the company’s
- GlobeNewswire
Saniona progresses its Kv7 epilepsy program into Lead Optimization
PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate. Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilep
- GlobeNewswire
Saniona provides update on outstanding option programs
PRESS RELEASE August 5, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that 6,450,734 options have forfeited in 2022, leading to a reduction in potential dilution from 11.89% to 3.06%. As of December 31, 2021, the company had 8,402,181 options outstanding entitling to the subscription of maximum 8,420,812 new shares representing a dilution of 11.89 percent. As of July 31, 2022, the company has 1,951,447 options outstanding entitling to the subscription of
- GlobeNewswire
Notice of extraordinary general meeting in Saniona AB
PRESS RELEASE 15 July 2022 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the extraordinary general meeting on Thursday 18 August 2022 at 15:00 (CEST) to be held at the premises of Setterwalls Advokatbyrå AB at Stortorget 23 in Malmö, Sweden. Right to participate and notice of participation Shareholde
- GlobeNewswire
Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market
PRESS RELEASE July 6, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the CEO and a member of the Board of Directors have purchased 240,221 shares of the company in the open market for a total value of approximately SEK 0.9 million. Saniona CEO Thomas Feldthus bought 200,221 shares in the company for a total investment of SEK 785,683. Saniona board member Carl Johan Sundberg bought 40,000 shares in the company for a total investment of SEK 142,128. Al
- GlobeNewswire
Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial
PRESS RELEASE June 30, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has successfully completed its Phase 1 clinical trial of SAN711, which is positioned for the treatment of neuropathic pain disorders. Data from the trial demonstrated that SAN711 was safe and well tolerated across all dosing cohorts with a favorable absorption and distribution profile. There were no serious adverse events, and all subjects completed the study. Long term dosing w
- GlobeNewswire
Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model
PRESS RELEASE June 24, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that professor Helle Prætorius, Univ. of Aarhus, Denmark, made a presentation at the ECM conference, 2022, which shows that SAN903 protects against fibrosis in a chronic kindney dease model. Chronic kidney disease (CKD) is a devastating, progressive deterioration of renal function that significantly impacts the quality of life for the individual and represents a substantial cost for the